Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
17,797
archived clinical trials in
Peripheral Vascular Disease

The Evaluation of Bococizumab (PF-04950615;RN316) in Reducing the Occurrence of Major Cardiovascular Events in High Risk Subjects
Phase 3 Multi-center, Double-blind, Randomized, Placebo-controlled, Parallel Group Evaluation Of The Efficacy, Safety, And Tolerability Of Bococizumab (Pf-04950615) In Reducing The Occurrence Of Major Cardiovascular Events In High Risk Subjects.
Status: Enrolling
Updated:  12/31/1969
Advance Medical Research
mi
from
Saint Petersburg, FL
The Evaluation of Bococizumab (PF-04950615;RN316) in Reducing the Occurrence of Major Cardiovascular Events in High Risk Subjects
Phase 3 Multi-center, Double-blind, Randomized, Placebo-controlled, Parallel Group Evaluation Of The Efficacy, Safety, And Tolerability Of Bococizumab (Pf-04950615) In Reducing The Occurrence Of Major Cardiovascular Events In High Risk Subjects.
Status: Enrolling
Updated: 12/31/1969
Advance Medical Research
mi
from
Saint Petersburg, FL
Click here to add this to my saved trials
The Evaluation of Bococizumab (PF-04950615;RN316) in Reducing the Occurrence of Major Cardiovascular Events in High Risk Subjects
Phase 3 Multi-center, Double-blind, Randomized, Placebo-controlled, Parallel Group Evaluation Of The Efficacy, Safety, And Tolerability Of Bococizumab (Pf-04950615) In Reducing The Occurrence Of Major Cardiovascular Events In High Risk Subjects.
Status: Enrolling
Updated:  12/31/1969
KAMP Medical Research
mi
from
Natchitoches, LA
The Evaluation of Bococizumab (PF-04950615;RN316) in Reducing the Occurrence of Major Cardiovascular Events in High Risk Subjects
Phase 3 Multi-center, Double-blind, Randomized, Placebo-controlled, Parallel Group Evaluation Of The Efficacy, Safety, And Tolerability Of Bococizumab (Pf-04950615) In Reducing The Occurrence Of Major Cardiovascular Events In High Risk Subjects.
Status: Enrolling
Updated: 12/31/1969
KAMP Medical Research
mi
from
Natchitoches, LA
Click here to add this to my saved trials
The Evaluation of Bococizumab (PF-04950615;RN316) in Reducing the Occurrence of Major Cardiovascular Events in High Risk Subjects
Phase 3 Multi-center, Double-blind, Randomized, Placebo-controlled, Parallel Group Evaluation Of The Efficacy, Safety, And Tolerability Of Bococizumab (Pf-04950615) In Reducing The Occurrence Of Major Cardiovascular Events In High Risk Subjects.
Status: Enrolling
Updated:  12/31/1969
CentraCare Heart & Vascular Center
mi
from
Saint Cloud, MN
The Evaluation of Bococizumab (PF-04950615;RN316) in Reducing the Occurrence of Major Cardiovascular Events in High Risk Subjects
Phase 3 Multi-center, Double-blind, Randomized, Placebo-controlled, Parallel Group Evaluation Of The Efficacy, Safety, And Tolerability Of Bococizumab (Pf-04950615) In Reducing The Occurrence Of Major Cardiovascular Events In High Risk Subjects.
Status: Enrolling
Updated: 12/31/1969
CentraCare Heart & Vascular Center
mi
from
Saint Cloud, MN
Click here to add this to my saved trials
The Evaluation of Bococizumab (PF-04950615;RN316) in Reducing the Occurrence of Major Cardiovascular Events in High Risk Subjects
Phase 3 Multi-center, Double-blind, Randomized, Placebo-controlled, Parallel Group Evaluation Of The Efficacy, Safety, And Tolerability Of Bococizumab (Pf-04950615) In Reducing The Occurrence Of Major Cardiovascular Events In High Risk Subjects.
Status: Enrolling
Updated:  12/31/1969
HealthEast Medical Research Institute
mi
from
Saint Paul, MN
The Evaluation of Bococizumab (PF-04950615;RN316) in Reducing the Occurrence of Major Cardiovascular Events in High Risk Subjects
Phase 3 Multi-center, Double-blind, Randomized, Placebo-controlled, Parallel Group Evaluation Of The Efficacy, Safety, And Tolerability Of Bococizumab (Pf-04950615) In Reducing The Occurrence Of Major Cardiovascular Events In High Risk Subjects.
Status: Enrolling
Updated: 12/31/1969
HealthEast Medical Research Institute
mi
from
Saint Paul, MN
Click here to add this to my saved trials
The Evaluation of Bococizumab (PF-04950615;RN316) in Reducing the Occurrence of Major Cardiovascular Events in High Risk Subjects
Phase 3 Multi-center, Double-blind, Randomized, Placebo-controlled, Parallel Group Evaluation Of The Efficacy, Safety, And Tolerability Of Bococizumab (Pf-04950615) In Reducing The Occurrence Of Major Cardiovascular Events In High Risk Subjects.
Status: Enrolling
Updated:  12/31/1969
HealthEast St. Joseph's Hospital Pharmacy
mi
from
Saint Paul, MN
The Evaluation of Bococizumab (PF-04950615;RN316) in Reducing the Occurrence of Major Cardiovascular Events in High Risk Subjects
Phase 3 Multi-center, Double-blind, Randomized, Placebo-controlled, Parallel Group Evaluation Of The Efficacy, Safety, And Tolerability Of Bococizumab (Pf-04950615) In Reducing The Occurrence Of Major Cardiovascular Events In High Risk Subjects.
Status: Enrolling
Updated: 12/31/1969
HealthEast St. Joseph's Hospital Pharmacy
mi
from
Saint Paul, MN
Click here to add this to my saved trials
The Evaluation of Bococizumab (PF-04950615;RN316) in Reducing the Occurrence of Major Cardiovascular Events in High Risk Subjects
Phase 3 Multi-center, Double-blind, Randomized, Placebo-controlled, Parallel Group Evaluation Of The Efficacy, Safety, And Tolerability Of Bococizumab (Pf-04950615) In Reducing The Occurrence Of Major Cardiovascular Events In High Risk Subjects.
Status: Enrolling
Updated:  12/31/1969
Mercy Research
mi
from
Saint Louis, MO
The Evaluation of Bococizumab (PF-04950615;RN316) in Reducing the Occurrence of Major Cardiovascular Events in High Risk Subjects
Phase 3 Multi-center, Double-blind, Randomized, Placebo-controlled, Parallel Group Evaluation Of The Efficacy, Safety, And Tolerability Of Bococizumab (Pf-04950615) In Reducing The Occurrence Of Major Cardiovascular Events In High Risk Subjects.
Status: Enrolling
Updated: 12/31/1969
Mercy Research
mi
from
Saint Louis, MO
Click here to add this to my saved trials
The Evaluation of Bococizumab (PF-04950615;RN316) in Reducing the Occurrence of Major Cardiovascular Events in High Risk Subjects
Phase 3 Multi-center, Double-blind, Randomized, Placebo-controlled, Parallel Group Evaluation Of The Efficacy, Safety, And Tolerability Of Bococizumab (Pf-04950615) In Reducing The Occurrence Of Major Cardiovascular Events In High Risk Subjects.
Status: Enrolling
Updated:  12/31/1969
Manhattan Medical Research Practice PLLC
mi
from
New York, NY
The Evaluation of Bococizumab (PF-04950615;RN316) in Reducing the Occurrence of Major Cardiovascular Events in High Risk Subjects
Phase 3 Multi-center, Double-blind, Randomized, Placebo-controlled, Parallel Group Evaluation Of The Efficacy, Safety, And Tolerability Of Bococizumab (Pf-04950615) In Reducing The Occurrence Of Major Cardiovascular Events In High Risk Subjects.
Status: Enrolling
Updated: 12/31/1969
Manhattan Medical Research Practice PLLC
mi
from
New York, NY
Click here to add this to my saved trials
The Evaluation of Bococizumab (PF-04950615;RN316) in Reducing the Occurrence of Major Cardiovascular Events in High Risk Subjects
Phase 3 Multi-center, Double-blind, Randomized, Placebo-controlled, Parallel Group Evaluation Of The Efficacy, Safety, And Tolerability Of Bococizumab (Pf-04950615) In Reducing The Occurrence Of Major Cardiovascular Events In High Risk Subjects.
Status: Enrolling
Updated:  12/31/1969
Amh/Feasterville Family Health Care Center
mi
from
Feasterville-Trevose, PA
The Evaluation of Bococizumab (PF-04950615;RN316) in Reducing the Occurrence of Major Cardiovascular Events in High Risk Subjects
Phase 3 Multi-center, Double-blind, Randomized, Placebo-controlled, Parallel Group Evaluation Of The Efficacy, Safety, And Tolerability Of Bococizumab (Pf-04950615) In Reducing The Occurrence Of Major Cardiovascular Events In High Risk Subjects.
Status: Enrolling
Updated: 12/31/1969
Amh/Feasterville Family Health Care Center
mi
from
Feasterville-Trevose, PA
Click here to add this to my saved trials
The Evaluation of Bococizumab (PF-04950615;RN316) in Reducing the Occurrence of Major Cardiovascular Events in High Risk Subjects
Phase 3 Multi-center, Double-blind, Randomized, Placebo-controlled, Parallel Group Evaluation Of The Efficacy, Safety, And Tolerability Of Bococizumab (Pf-04950615) In Reducing The Occurrence Of Major Cardiovascular Events In High Risk Subjects.
Status: Enrolling
Updated:  12/31/1969
Arkansas Heart Hospital/Clinic
mi
from
Little Rock, AR
The Evaluation of Bococizumab (PF-04950615;RN316) in Reducing the Occurrence of Major Cardiovascular Events in High Risk Subjects
Phase 3 Multi-center, Double-blind, Randomized, Placebo-controlled, Parallel Group Evaluation Of The Efficacy, Safety, And Tolerability Of Bococizumab (Pf-04950615) In Reducing The Occurrence Of Major Cardiovascular Events In High Risk Subjects.
Status: Enrolling
Updated: 12/31/1969
Arkansas Heart Hospital/Clinic
mi
from
Little Rock, AR
Click here to add this to my saved trials
The Evaluation of Bococizumab (PF-04950615;RN316) in Reducing the Occurrence of Major Cardiovascular Events in High Risk Subjects
Phase 3 Multi-center, Double-blind, Randomized, Placebo-controlled, Parallel Group Evaluation Of The Efficacy, Safety, And Tolerability Of Bococizumab (Pf-04950615) In Reducing The Occurrence Of Major Cardiovascular Events In High Risk Subjects.
Status: Enrolling
Updated:  12/31/1969
Advanced Clinical Research of Miami (ACROM) International
mi
from
Miami, FL
The Evaluation of Bococizumab (PF-04950615;RN316) in Reducing the Occurrence of Major Cardiovascular Events in High Risk Subjects
Phase 3 Multi-center, Double-blind, Randomized, Placebo-controlled, Parallel Group Evaluation Of The Efficacy, Safety, And Tolerability Of Bococizumab (Pf-04950615) In Reducing The Occurrence Of Major Cardiovascular Events In High Risk Subjects.
Status: Enrolling
Updated: 12/31/1969
Advanced Clinical Research of Miami (ACROM) International
mi
from
Miami, FL
Click here to add this to my saved trials
The Evaluation of Bococizumab (PF-04950615;RN316) in Reducing the Occurrence of Major Cardiovascular Events in High Risk Subjects
Phase 3 Multi-center, Double-blind, Randomized, Placebo-controlled, Parallel Group Evaluation Of The Efficacy, Safety, And Tolerability Of Bococizumab (Pf-04950615) In Reducing The Occurrence Of Major Cardiovascular Events In High Risk Subjects.
Status: Enrolling
Updated:  12/31/1969
BWell Research Center
mi
from
Miami, FL
The Evaluation of Bococizumab (PF-04950615;RN316) in Reducing the Occurrence of Major Cardiovascular Events in High Risk Subjects
Phase 3 Multi-center, Double-blind, Randomized, Placebo-controlled, Parallel Group Evaluation Of The Efficacy, Safety, And Tolerability Of Bococizumab (Pf-04950615) In Reducing The Occurrence Of Major Cardiovascular Events In High Risk Subjects.
Status: Enrolling
Updated: 12/31/1969
BWell Research Center
mi
from
Miami, FL
Click here to add this to my saved trials
The Evaluation of Bococizumab (PF-04950615;RN316) in Reducing the Occurrence of Major Cardiovascular Events in High Risk Subjects
Phase 3 Multi-center, Double-blind, Randomized, Placebo-controlled, Parallel Group Evaluation Of The Efficacy, Safety, And Tolerability Of Bococizumab (Pf-04950615) In Reducing The Occurrence Of Major Cardiovascular Events In High Risk Subjects.
Status: Enrolling
Updated:  12/31/1969
BayCare Medical Group
mi
from
New Port Richey, FL
The Evaluation of Bococizumab (PF-04950615;RN316) in Reducing the Occurrence of Major Cardiovascular Events in High Risk Subjects
Phase 3 Multi-center, Double-blind, Randomized, Placebo-controlled, Parallel Group Evaluation Of The Efficacy, Safety, And Tolerability Of Bococizumab (Pf-04950615) In Reducing The Occurrence Of Major Cardiovascular Events In High Risk Subjects.
Status: Enrolling
Updated: 12/31/1969
BayCare Medical Group
mi
from
New Port Richey, FL
Click here to add this to my saved trials
The Evaluation of Bococizumab (PF-04950615;RN316) in Reducing the Occurrence of Major Cardiovascular Events in High Risk Subjects
Phase 3 Multi-center, Double-blind, Randomized, Placebo-controlled, Parallel Group Evaluation Of The Efficacy, Safety, And Tolerability Of Bococizumab (Pf-04950615) In Reducing The Occurrence Of Major Cardiovascular Events In High Risk Subjects.
Status: Enrolling
Updated:  12/31/1969
Dr. Jeffrey Greiff MD, Office Of
mi
from
Plantation, FL
The Evaluation of Bococizumab (PF-04950615;RN316) in Reducing the Occurrence of Major Cardiovascular Events in High Risk Subjects
Phase 3 Multi-center, Double-blind, Randomized, Placebo-controlled, Parallel Group Evaluation Of The Efficacy, Safety, And Tolerability Of Bococizumab (Pf-04950615) In Reducing The Occurrence Of Major Cardiovascular Events In High Risk Subjects.
Status: Enrolling
Updated: 12/31/1969
Dr. Jeffrey Greiff MD, Office Of
mi
from
Plantation, FL
Click here to add this to my saved trials
The Evaluation of Bococizumab (PF-04950615;RN316) in Reducing the Occurrence of Major Cardiovascular Events in High Risk Subjects
Phase 3 Multi-center, Double-blind, Randomized, Placebo-controlled, Parallel Group Evaluation Of The Efficacy, Safety, And Tolerability Of Bococizumab (Pf-04950615) In Reducing The Occurrence Of Major Cardiovascular Events In High Risk Subjects.
Status: Enrolling
Updated:  12/31/1969
Elite Clinial Trials, LLLP
mi
from
Blackfoot, ID
The Evaluation of Bococizumab (PF-04950615;RN316) in Reducing the Occurrence of Major Cardiovascular Events in High Risk Subjects
Phase 3 Multi-center, Double-blind, Randomized, Placebo-controlled, Parallel Group Evaluation Of The Efficacy, Safety, And Tolerability Of Bococizumab (Pf-04950615) In Reducing The Occurrence Of Major Cardiovascular Events In High Risk Subjects.
Status: Enrolling
Updated: 12/31/1969
Elite Clinial Trials, LLLP
mi
from
Blackfoot, ID
Click here to add this to my saved trials
The Evaluation of Bococizumab (PF-04950615;RN316) in Reducing the Occurrence of Major Cardiovascular Events in High Risk Subjects
Phase 3 Multi-center, Double-blind, Randomized, Placebo-controlled, Parallel Group Evaluation Of The Efficacy, Safety, And Tolerability Of Bococizumab (Pf-04950615) In Reducing The Occurrence Of Major Cardiovascular Events In High Risk Subjects.
Status: Enrolling
Updated:  12/31/1969
Clinical Research Advantage
mi
from
Council Bluffs, IA
The Evaluation of Bococizumab (PF-04950615;RN316) in Reducing the Occurrence of Major Cardiovascular Events in High Risk Subjects
Phase 3 Multi-center, Double-blind, Randomized, Placebo-controlled, Parallel Group Evaluation Of The Efficacy, Safety, And Tolerability Of Bococizumab (Pf-04950615) In Reducing The Occurrence Of Major Cardiovascular Events In High Risk Subjects.
Status: Enrolling
Updated: 12/31/1969
Clinical Research Advantage
mi
from
Council Bluffs, IA
Click here to add this to my saved trials
The Evaluation of Bococizumab (PF-04950615;RN316) in Reducing the Occurrence of Major Cardiovascular Events in High Risk Subjects
Phase 3 Multi-center, Double-blind, Randomized, Placebo-controlled, Parallel Group Evaluation Of The Efficacy, Safety, And Tolerability Of Bococizumab (Pf-04950615) In Reducing The Occurrence Of Major Cardiovascular Events In High Risk Subjects.
Status: Enrolling
Updated:  12/31/1969
Duluth Clinic, dba Essentia Health Duluth Clinic Investigational Drug Room
mi
from
Duluth, MN
The Evaluation of Bococizumab (PF-04950615;RN316) in Reducing the Occurrence of Major Cardiovascular Events in High Risk Subjects
Phase 3 Multi-center, Double-blind, Randomized, Placebo-controlled, Parallel Group Evaluation Of The Efficacy, Safety, And Tolerability Of Bococizumab (Pf-04950615) In Reducing The Occurrence Of Major Cardiovascular Events In High Risk Subjects.
Status: Enrolling
Updated: 12/31/1969
Duluth Clinic, dba Essentia Health Duluth Clinic Investigational Drug Room
mi
from
Duluth, MN
Click here to add this to my saved trials
The Evaluation of Bococizumab (PF-04950615;RN316) in Reducing the Occurrence of Major Cardiovascular Events in High Risk Subjects
Phase 3 Multi-center, Double-blind, Randomized, Placebo-controlled, Parallel Group Evaluation Of The Efficacy, Safety, And Tolerability Of Bococizumab (Pf-04950615) In Reducing The Occurrence Of Major Cardiovascular Events In High Risk Subjects.
Status: Enrolling
Updated:  12/31/1969
St. Mary's Medical Center (Primary Practice Site)
mi
from
Duluth, MN
The Evaluation of Bococizumab (PF-04950615;RN316) in Reducing the Occurrence of Major Cardiovascular Events in High Risk Subjects
Phase 3 Multi-center, Double-blind, Randomized, Placebo-controlled, Parallel Group Evaluation Of The Efficacy, Safety, And Tolerability Of Bococizumab (Pf-04950615) In Reducing The Occurrence Of Major Cardiovascular Events In High Risk Subjects.
Status: Enrolling
Updated: 12/31/1969
St. Mary's Medical Center (Primary Practice Site)
mi
from
Duluth, MN
Click here to add this to my saved trials
The Evaluation of Bococizumab (PF-04950615;RN316) in Reducing the Occurrence of Major Cardiovascular Events in High Risk Subjects
Phase 3 Multi-center, Double-blind, Randomized, Placebo-controlled, Parallel Group Evaluation Of The Efficacy, Safety, And Tolerability Of Bococizumab (Pf-04950615) In Reducing The Occurrence Of Major Cardiovascular Events In High Risk Subjects.
Status: Enrolling
Updated:  12/31/1969
Cardiac and Endovascular Associates
mi
from
Ridgewood, NJ
The Evaluation of Bococizumab (PF-04950615;RN316) in Reducing the Occurrence of Major Cardiovascular Events in High Risk Subjects
Phase 3 Multi-center, Double-blind, Randomized, Placebo-controlled, Parallel Group Evaluation Of The Efficacy, Safety, And Tolerability Of Bococizumab (Pf-04950615) In Reducing The Occurrence Of Major Cardiovascular Events In High Risk Subjects.
Status: Enrolling
Updated: 12/31/1969
Cardiac and Endovascular Associates
mi
from
Ridgewood, NJ
Click here to add this to my saved trials
The Evaluation of Bococizumab (PF-04950615;RN316) in Reducing the Occurrence of Major Cardiovascular Events in High Risk Subjects
Phase 3 Multi-center, Double-blind, Randomized, Placebo-controlled, Parallel Group Evaluation Of The Efficacy, Safety, And Tolerability Of Bococizumab (Pf-04950615) In Reducing The Occurrence Of Major Cardiovascular Events In High Risk Subjects.
Status: Enrolling
Updated:  12/31/1969
Scott Research, Inc.
mi
from
Laurelton, NY
The Evaluation of Bococizumab (PF-04950615;RN316) in Reducing the Occurrence of Major Cardiovascular Events in High Risk Subjects
Phase 3 Multi-center, Double-blind, Randomized, Placebo-controlled, Parallel Group Evaluation Of The Efficacy, Safety, And Tolerability Of Bococizumab (Pf-04950615) In Reducing The Occurrence Of Major Cardiovascular Events In High Risk Subjects.
Status: Enrolling
Updated: 12/31/1969
Scott Research, Inc.
mi
from
Laurelton, NY
Click here to add this to my saved trials
The Evaluation of Bococizumab (PF-04950615;RN316) in Reducing the Occurrence of Major Cardiovascular Events in High Risk Subjects
Phase 3 Multi-center, Double-blind, Randomized, Placebo-controlled, Parallel Group Evaluation Of The Efficacy, Safety, And Tolerability Of Bococizumab (Pf-04950615) In Reducing The Occurrence Of Major Cardiovascular Events In High Risk Subjects.
Status: Enrolling
Updated:  12/31/1969
Premier Health Specialists, Inc (dba Dayton Heart Center)
mi
from
Dayton, OH
The Evaluation of Bococizumab (PF-04950615;RN316) in Reducing the Occurrence of Major Cardiovascular Events in High Risk Subjects
Phase 3 Multi-center, Double-blind, Randomized, Placebo-controlled, Parallel Group Evaluation Of The Efficacy, Safety, And Tolerability Of Bococizumab (Pf-04950615) In Reducing The Occurrence Of Major Cardiovascular Events In High Risk Subjects.
Status: Enrolling
Updated: 12/31/1969
Premier Health Specialists, Inc (dba Dayton Heart Center)
mi
from
Dayton, OH
Click here to add this to my saved trials
The Evaluation of Bococizumab (PF-04950615;RN316) in Reducing the Occurrence of Major Cardiovascular Events in High Risk Subjects
Phase 3 Multi-center, Double-blind, Randomized, Placebo-controlled, Parallel Group Evaluation Of The Efficacy, Safety, And Tolerability Of Bococizumab (Pf-04950615) In Reducing The Occurrence Of Major Cardiovascular Events In High Risk Subjects.
Status: Enrolling
Updated:  12/31/1969
North Ohio Heart Center (Administrative Only)
mi
from
Elyria, OH
The Evaluation of Bococizumab (PF-04950615;RN316) in Reducing the Occurrence of Major Cardiovascular Events in High Risk Subjects
Phase 3 Multi-center, Double-blind, Randomized, Placebo-controlled, Parallel Group Evaluation Of The Efficacy, Safety, And Tolerability Of Bococizumab (Pf-04950615) In Reducing The Occurrence Of Major Cardiovascular Events In High Risk Subjects.
Status: Enrolling
Updated: 12/31/1969
North Ohio Heart Center (Administrative Only)
mi
from
Elyria, OH
Click here to add this to my saved trials
The Evaluation of Bococizumab (PF-04950615;RN316) in Reducing the Occurrence of Major Cardiovascular Events in High Risk Subjects
Phase 3 Multi-center, Double-blind, Randomized, Placebo-controlled, Parallel Group Evaluation Of The Efficacy, Safety, And Tolerability Of Bococizumab (Pf-04950615) In Reducing The Occurrence Of Major Cardiovascular Events In High Risk Subjects.
Status: Enrolling
Updated:  12/31/1969
North Ohio Heart Center
mi
from
Elyria, OH
The Evaluation of Bococizumab (PF-04950615;RN316) in Reducing the Occurrence of Major Cardiovascular Events in High Risk Subjects
Phase 3 Multi-center, Double-blind, Randomized, Placebo-controlled, Parallel Group Evaluation Of The Efficacy, Safety, And Tolerability Of Bococizumab (Pf-04950615) In Reducing The Occurrence Of Major Cardiovascular Events In High Risk Subjects.
Status: Enrolling
Updated: 12/31/1969
North Ohio Heart Center
mi
from
Elyria, OH
Click here to add this to my saved trials
The Evaluation of Bococizumab (PF-04950615;RN316) in Reducing the Occurrence of Major Cardiovascular Events in High Risk Subjects
Phase 3 Multi-center, Double-blind, Randomized, Placebo-controlled, Parallel Group Evaluation Of The Efficacy, Safety, And Tolerability Of Bococizumab (Pf-04950615) In Reducing The Occurrence Of Major Cardiovascular Events In High Risk Subjects.
Status: Enrolling
Updated:  12/31/1969
IP + Dry ice deliveries Sugar Lakes Family Practice
mi
from
Sugar Land, TX
The Evaluation of Bococizumab (PF-04950615;RN316) in Reducing the Occurrence of Major Cardiovascular Events in High Risk Subjects
Phase 3 Multi-center, Double-blind, Randomized, Placebo-controlled, Parallel Group Evaluation Of The Efficacy, Safety, And Tolerability Of Bococizumab (Pf-04950615) In Reducing The Occurrence Of Major Cardiovascular Events In High Risk Subjects.
Status: Enrolling
Updated: 12/31/1969
IP + Dry ice deliveries Sugar Lakes Family Practice
mi
from
Sugar Land, TX
Click here to add this to my saved trials
The Evaluation of Bococizumab (PF-04950615;RN316) in Reducing the Occurrence of Major Cardiovascular Events in High Risk Subjects
Phase 3 Multi-center, Double-blind, Randomized, Placebo-controlled, Parallel Group Evaluation Of The Efficacy, Safety, And Tolerability Of Bococizumab (Pf-04950615) In Reducing The Occurrence Of Major Cardiovascular Events In High Risk Subjects.
Status: Enrolling
Updated:  12/31/1969
Northwest Houston Heart Center
mi
from
Tomball, TX
The Evaluation of Bococizumab (PF-04950615;RN316) in Reducing the Occurrence of Major Cardiovascular Events in High Risk Subjects
Phase 3 Multi-center, Double-blind, Randomized, Placebo-controlled, Parallel Group Evaluation Of The Efficacy, Safety, And Tolerability Of Bococizumab (Pf-04950615) In Reducing The Occurrence Of Major Cardiovascular Events In High Risk Subjects.
Status: Enrolling
Updated: 12/31/1969
Northwest Houston Heart Center
mi
from
Tomball, TX
Click here to add this to my saved trials
The Evaluation of Bococizumab (PF-04950615;RN316) in Reducing the Occurrence of Major Cardiovascular Events in High Risk Subjects
Phase 3 Multi-center, Double-blind, Randomized, Placebo-controlled, Parallel Group Evaluation Of The Efficacy, Safety, And Tolerability Of Bococizumab (Pf-04950615) In Reducing The Occurrence Of Major Cardiovascular Events In High Risk Subjects.
Status: Enrolling
Updated:  12/31/1969
Admin & Storage only:Northwest Heart Center
mi
from
Tomball, TX
The Evaluation of Bococizumab (PF-04950615;RN316) in Reducing the Occurrence of Major Cardiovascular Events in High Risk Subjects
Phase 3 Multi-center, Double-blind, Randomized, Placebo-controlled, Parallel Group Evaluation Of The Efficacy, Safety, And Tolerability Of Bococizumab (Pf-04950615) In Reducing The Occurrence Of Major Cardiovascular Events In High Risk Subjects.
Status: Enrolling
Updated: 12/31/1969
Admin & Storage only:Northwest Heart Center
mi
from
Tomball, TX
Click here to add this to my saved trials
The Evaluation of Bococizumab (PF-04950615;RN316) in Reducing the Occurrence of Major Cardiovascular Events in High Risk Subjects
Phase 3 Multi-center, Double-blind, Randomized, Placebo-controlled, Parallel Group Evaluation Of The Efficacy, Safety, And Tolerability Of Bococizumab (Pf-04950615) In Reducing The Occurrence Of Major Cardiovascular Events In High Risk Subjects.
Status: Enrolling
Updated:  12/31/1969
Capital Medical Associates, PC
mi
from
Washington,
The Evaluation of Bococizumab (PF-04950615;RN316) in Reducing the Occurrence of Major Cardiovascular Events in High Risk Subjects
Phase 3 Multi-center, Double-blind, Randomized, Placebo-controlled, Parallel Group Evaluation Of The Efficacy, Safety, And Tolerability Of Bococizumab (Pf-04950615) In Reducing The Occurrence Of Major Cardiovascular Events In High Risk Subjects.
Status: Enrolling
Updated: 12/31/1969
Capital Medical Associates, PC
mi
from
Washington,
Click here to add this to my saved trials
The Evaluation of Bococizumab (PF-04950615;RN316) in Reducing the Occurrence of Major Cardiovascular Events in High Risk Subjects
Phase 3 Multi-center, Double-blind, Randomized, Placebo-controlled, Parallel Group Evaluation Of The Efficacy, Safety, And Tolerability Of Bococizumab (Pf-04950615) In Reducing The Occurrence Of Major Cardiovascular Events In High Risk Subjects.
Status: Enrolling
Updated:  12/31/1969
Women's & Family Care, LLC D.B.A GTC Research
mi
from
Shawnee Mission, KA
The Evaluation of Bococizumab (PF-04950615;RN316) in Reducing the Occurrence of Major Cardiovascular Events in High Risk Subjects
Phase 3 Multi-center, Double-blind, Randomized, Placebo-controlled, Parallel Group Evaluation Of The Efficacy, Safety, And Tolerability Of Bococizumab (Pf-04950615) In Reducing The Occurrence Of Major Cardiovascular Events In High Risk Subjects.
Status: Enrolling
Updated: 12/31/1969
Women's & Family Care, LLC D.B.A GTC Research
mi
from
Shawnee Mission, KA
Click here to add this to my saved trials
The Evaluation of Bococizumab (PF-04950615;RN316) in Reducing the Occurrence of Major Cardiovascular Events in High Risk Subjects
Phase 3 Multi-center, Double-blind, Randomized, Placebo-controlled, Parallel Group Evaluation Of The Efficacy, Safety, And Tolerability Of Bococizumab (Pf-04950615) In Reducing The Occurrence Of Major Cardiovascular Events In High Risk Subjects.
Status: Enrolling
Updated:  12/31/1969
NYU Hudson Valley Cardiology
mi
from
Cortlandt Manor, NY
The Evaluation of Bococizumab (PF-04950615;RN316) in Reducing the Occurrence of Major Cardiovascular Events in High Risk Subjects
Phase 3 Multi-center, Double-blind, Randomized, Placebo-controlled, Parallel Group Evaluation Of The Efficacy, Safety, And Tolerability Of Bococizumab (Pf-04950615) In Reducing The Occurrence Of Major Cardiovascular Events In High Risk Subjects.
Status: Enrolling
Updated: 12/31/1969
NYU Hudson Valley Cardiology
mi
from
Cortlandt Manor, NY
Click here to add this to my saved trials
Obstructive Sleep Apnea Treatment to Improve Cardiac Rehabilitation
Obstructive Sleep Apnea Treatment to Improve Cardiac Rehabilitation
Status: Enrolling
Updated:  12/31/1969
VA Boston Healthcare System Jamaica Plain Campus, Jamaica Plain, MA
mi
from
Boston, MA
Obstructive Sleep Apnea Treatment to Improve Cardiac Rehabilitation
Obstructive Sleep Apnea Treatment to Improve Cardiac Rehabilitation
Status: Enrolling
Updated: 12/31/1969
VA Boston Healthcare System Jamaica Plain Campus, Jamaica Plain, MA
mi
from
Boston, MA
Click here to add this to my saved trials
Assessment of Coronary Artery Calcium in Active Duty Enlisted Military Members With 10 or More Years of Service
Assessment of Coronary Artery Calcium in Active Duty Enlisted Military Members With 10 or More Years of Service
Status: Enrolling
Updated:  12/31/1969
David Grant USAF Medical Center
mi
from
Travis Air Force Base, CA
Assessment of Coronary Artery Calcium in Active Duty Enlisted Military Members With 10 or More Years of Service
Assessment of Coronary Artery Calcium in Active Duty Enlisted Military Members With 10 or More Years of Service
Status: Enrolling
Updated: 12/31/1969
David Grant USAF Medical Center
mi
from
Travis Air Force Base, CA
Click here to add this to my saved trials
A Phase IIB Pilot Study of a Modified Dosage Regimen of AMG0001 in Subjects With Critical Limb Ischemia
A Phase IIB Pilot Study to Confirm the Feasibility and Tolerability of a Modified Dosage Regimen of AMG0001 in Subjects With Critical Limb Ischemia
Status: Enrolling
Updated:  12/31/1969
Dartmouth Hitchcock Medical Center
mi
from
Lebanon, NH
A Phase IIB Pilot Study of a Modified Dosage Regimen of AMG0001 in Subjects With Critical Limb Ischemia
A Phase IIB Pilot Study to Confirm the Feasibility and Tolerability of a Modified Dosage Regimen of AMG0001 in Subjects With Critical Limb Ischemia
Status: Enrolling
Updated: 12/31/1969
Dartmouth Hitchcock Medical Center
mi
from
Lebanon, NH
Click here to add this to my saved trials
Center for Stroke Disparities Solution - Community Transitions Intervention
Center for Stroke Disparities Solution (CSDS) Project II: Community Transitions Intervention (CTI)
Status: Enrolling
Updated:  12/31/1969
Visiting Nurse Service of New York
mi
from
New York, NY
Center for Stroke Disparities Solution - Community Transitions Intervention
Center for Stroke Disparities Solution (CSDS) Project II: Community Transitions Intervention (CTI)
Status: Enrolling
Updated: 12/31/1969
Visiting Nurse Service of New York
mi
from
New York, NY
Click here to add this to my saved trials
Ancillary Effects of Dexmedetomidine Sedation After Cardiac Surgery
Ancillary Effects of Dexmedetomidine Sedation After Cardiac Surgery
Status: Enrolling
Updated:  12/31/1969
Cleveland Clinic Main
mi
from
Cleveland, OH
Ancillary Effects of Dexmedetomidine Sedation After Cardiac Surgery
Ancillary Effects of Dexmedetomidine Sedation After Cardiac Surgery
Status: Enrolling
Updated: 12/31/1969
Cleveland Clinic Main
mi
from
Cleveland, OH
Click here to add this to my saved trials
Outcomes, Patient Health Status, and Efficiency in Chronic Total Occlusion
Outcomes, Patient Health Status, and Efficiency in Chronic Total Occlusion (OPEN CTO)
Status: Enrolling
Updated:  12/31/1969
Banner Heart Hospital
mi
from
Mesa, AZ
Outcomes, Patient Health Status, and Efficiency in Chronic Total Occlusion
Outcomes, Patient Health Status, and Efficiency in Chronic Total Occlusion (OPEN CTO)
Status: Enrolling
Updated: 12/31/1969
Banner Heart Hospital
mi
from
Mesa, AZ
Click here to add this to my saved trials
Outcomes, Patient Health Status, and Efficiency in Chronic Total Occlusion
Outcomes, Patient Health Status, and Efficiency in Chronic Total Occlusion (OPEN CTO)
Status: Enrolling
Updated:  12/31/1969
Banner Good Samaritan
mi
from
Phoenix, AZ
Outcomes, Patient Health Status, and Efficiency in Chronic Total Occlusion
Outcomes, Patient Health Status, and Efficiency in Chronic Total Occlusion (OPEN CTO)
Status: Enrolling
Updated: 12/31/1969
Banner Good Samaritan
mi
from
Phoenix, AZ
Click here to add this to my saved trials
Outcomes, Patient Health Status, and Efficiency in Chronic Total Occlusion
Outcomes, Patient Health Status, and Efficiency in Chronic Total Occlusion (OPEN CTO)
Status: Enrolling
Updated:  12/31/1969
Torrance Memorial Medical Center
mi
from
Torrance, CA
Outcomes, Patient Health Status, and Efficiency in Chronic Total Occlusion
Outcomes, Patient Health Status, and Efficiency in Chronic Total Occlusion (OPEN CTO)
Status: Enrolling
Updated: 12/31/1969
Torrance Memorial Medical Center
mi
from
Torrance, CA
Click here to add this to my saved trials
Outcomes, Patient Health Status, and Efficiency in Chronic Total Occlusion
Outcomes, Patient Health Status, and Efficiency in Chronic Total Occlusion (OPEN CTO)
Status: Enrolling
Updated:  12/31/1969
Alexian Brothers Medical Center
mi
from
Elk Grove Village, IL
Outcomes, Patient Health Status, and Efficiency in Chronic Total Occlusion
Outcomes, Patient Health Status, and Efficiency in Chronic Total Occlusion (OPEN CTO)
Status: Enrolling
Updated: 12/31/1969
Alexian Brothers Medical Center
mi
from
Elk Grove Village, IL
Click here to add this to my saved trials
Outcomes, Patient Health Status, and Efficiency in Chronic Total Occlusion
Outcomes, Patient Health Status, and Efficiency in Chronic Total Occlusion (OPEN CTO)
Status: Enrolling
Updated:  12/31/1969
Boone Hospital Center
mi
from
Columbia, MO
Outcomes, Patient Health Status, and Efficiency in Chronic Total Occlusion
Outcomes, Patient Health Status, and Efficiency in Chronic Total Occlusion (OPEN CTO)
Status: Enrolling
Updated: 12/31/1969
Boone Hospital Center
mi
from
Columbia, MO
Click here to add this to my saved trials
Outcomes, Patient Health Status, and Efficiency in Chronic Total Occlusion
Outcomes, Patient Health Status, and Efficiency in Chronic Total Occlusion (OPEN CTO)
Status: Enrolling
Updated:  12/31/1969
Saint Luke's Hospital, Kansas City
mi
from
Kansas City, MO
Outcomes, Patient Health Status, and Efficiency in Chronic Total Occlusion
Outcomes, Patient Health Status, and Efficiency in Chronic Total Occlusion (OPEN CTO)
Status: Enrolling
Updated: 12/31/1969
Saint Luke's Hospital, Kansas City
mi
from
Kansas City, MO
Click here to add this to my saved trials
Outcomes, Patient Health Status, and Efficiency in Chronic Total Occlusion
Outcomes, Patient Health Status, and Efficiency in Chronic Total Occlusion (OPEN CTO)
Status: Enrolling
Updated:  12/31/1969
Presbyterian Health System Hospital
mi
from
Albuquerque, NM
Outcomes, Patient Health Status, and Efficiency in Chronic Total Occlusion
Outcomes, Patient Health Status, and Efficiency in Chronic Total Occlusion (OPEN CTO)
Status: Enrolling
Updated: 12/31/1969
Presbyterian Health System Hospital
mi
from
Albuquerque, NM
Click here to add this to my saved trials
Outcomes, Patient Health Status, and Efficiency in Chronic Total Occlusion
Outcomes, Patient Health Status, and Efficiency in Chronic Total Occlusion (OPEN CTO)
Status: Enrolling
Updated:  12/31/1969
Peace Health Sacred Heart River Bend Medical Center
mi
from
Springfield, OR
Outcomes, Patient Health Status, and Efficiency in Chronic Total Occlusion
Outcomes, Patient Health Status, and Efficiency in Chronic Total Occlusion (OPEN CTO)
Status: Enrolling
Updated: 12/31/1969
Peace Health Sacred Heart River Bend Medical Center
mi
from
Springfield, OR
Click here to add this to my saved trials
Outcomes, Patient Health Status, and Efficiency in Chronic Total Occlusion
Outcomes, Patient Health Status, and Efficiency in Chronic Total Occlusion (OPEN CTO)
Status: Enrolling
Updated:  12/31/1969
University of Washington Medical Center
mi
from
Seattle, WA
Outcomes, Patient Health Status, and Efficiency in Chronic Total Occlusion
Outcomes, Patient Health Status, and Efficiency in Chronic Total Occlusion (OPEN CTO)
Status: Enrolling
Updated: 12/31/1969
University of Washington Medical Center
mi
from
Seattle, WA
Click here to add this to my saved trials
Outcomes, Patient Health Status, and Efficiency in Chronic Total Occlusion
Outcomes, Patient Health Status, and Efficiency in Chronic Total Occlusion (OPEN CTO)
Status: Enrolling
Updated:  12/31/1969
York Hospital
mi
from
York, PA
Outcomes, Patient Health Status, and Efficiency in Chronic Total Occlusion
Outcomes, Patient Health Status, and Efficiency in Chronic Total Occlusion (OPEN CTO)
Status: Enrolling
Updated: 12/31/1969
York Hospital
mi
from
York, PA
Click here to add this to my saved trials
Outcomes, Patient Health Status, and Efficiency in Chronic Total Occlusion
Outcomes, Patient Health Status, and Efficiency in Chronic Total Occlusion (OPEN CTO)
Status: Enrolling
Updated:  12/31/1969
Columbia University Medical Center
mi
from
New York, NY
Outcomes, Patient Health Status, and Efficiency in Chronic Total Occlusion
Outcomes, Patient Health Status, and Efficiency in Chronic Total Occlusion (OPEN CTO)
Status: Enrolling
Updated: 12/31/1969
Columbia University Medical Center
mi
from
New York, NY
Click here to add this to my saved trials
Point of Care (POC) Biomarkers of Ischemia
Point of Care (POC) Biomarkers of Ischemia
Status: Enrolling
Updated:  12/31/1969
Virginia Commonwealtlh University Health Systems
mi
from
Richmond, VA
Point of Care (POC) Biomarkers of Ischemia
Point of Care (POC) Biomarkers of Ischemia
Status: Enrolling
Updated: 12/31/1969
Virginia Commonwealtlh University Health Systems
mi
from
Richmond, VA
Click here to add this to my saved trials
Blended Collaborative Care for Heart Failure and Co-Morbid Depression
Blended Collaborative Care for Heart Failure and Co-Morbid Depression
Status: Enrolling
Updated:  12/31/1969
University of Pittsburgh
mi
from
Pittsburgh, PA
Blended Collaborative Care for Heart Failure and Co-Morbid Depression
Blended Collaborative Care for Heart Failure and Co-Morbid Depression
Status: Enrolling
Updated: 12/31/1969
University of Pittsburgh
mi
from
Pittsburgh, PA
Click here to add this to my saved trials
A Study to Evaluate the Effect of Long-term Treatment With BELVIQ (Lorcaserin HCl) on the Incidence of Major Adverse Cardiovascular Events and Conversion to Type 2 Diabetes Mellitus in Obese and Overweight Subjects With Cardiovascular Disease or Multiple Cardiovascular Risk Factors
A Randomized, Double-blind, Placebo-controlled, Parallel-group Study to Evaluate the Effect of Long-term Treatment With BELVIQ (Lorcaserin HCl) on the Incidence of Major Adverse Cardiovascular Events and Conversion to Type 2 Diabetes Mellitus in Obese and Overweight Subjects With Cardiovascular Disease or Multiple Cardiovascular Risk Factors
Status: Enrolling
Updated:  12/31/1969
Advanced Cardiovascular, LLC
mi
from
Alexander City, AL
A Study to Evaluate the Effect of Long-term Treatment With BELVIQ (Lorcaserin HCl) on the Incidence of Major Adverse Cardiovascular Events and Conversion to Type 2 Diabetes Mellitus in Obese and Overweight Subjects With Cardiovascular Disease or Multiple Cardiovascular Risk Factors
A Randomized, Double-blind, Placebo-controlled, Parallel-group Study to Evaluate the Effect of Long-term Treatment With BELVIQ (Lorcaserin HCl) on the Incidence of Major Adverse Cardiovascular Events and Conversion to Type 2 Diabetes Mellitus in Obese and Overweight Subjects With Cardiovascular Disease or Multiple Cardiovascular Risk Factors
Status: Enrolling
Updated: 12/31/1969
Advanced Cardiovascular, LLC
mi
from
Alexander City, AL
Click here to add this to my saved trials
A Study to Evaluate the Effect of Long-term Treatment With BELVIQ (Lorcaserin HCl) on the Incidence of Major Adverse Cardiovascular Events and Conversion to Type 2 Diabetes Mellitus in Obese and Overweight Subjects With Cardiovascular Disease or Multiple Cardiovascular Risk Factors
A Randomized, Double-blind, Placebo-controlled, Parallel-group Study to Evaluate the Effect of Long-term Treatment With BELVIQ (Lorcaserin HCl) on the Incidence of Major Adverse Cardiovascular Events and Conversion to Type 2 Diabetes Mellitus in Obese and Overweight Subjects With Cardiovascular Disease or Multiple Cardiovascular Risk Factors
Status: Enrolling
Updated:  12/31/1969
North Alabama Research Center
mi
from
Athens, AL
A Study to Evaluate the Effect of Long-term Treatment With BELVIQ (Lorcaserin HCl) on the Incidence of Major Adverse Cardiovascular Events and Conversion to Type 2 Diabetes Mellitus in Obese and Overweight Subjects With Cardiovascular Disease or Multiple Cardiovascular Risk Factors
A Randomized, Double-blind, Placebo-controlled, Parallel-group Study to Evaluate the Effect of Long-term Treatment With BELVIQ (Lorcaserin HCl) on the Incidence of Major Adverse Cardiovascular Events and Conversion to Type 2 Diabetes Mellitus in Obese and Overweight Subjects With Cardiovascular Disease or Multiple Cardiovascular Risk Factors
Status: Enrolling
Updated: 12/31/1969
North Alabama Research Center
mi
from
Athens, AL
Click here to add this to my saved trials
A Study to Evaluate the Effect of Long-term Treatment With BELVIQ (Lorcaserin HCl) on the Incidence of Major Adverse Cardiovascular Events and Conversion to Type 2 Diabetes Mellitus in Obese and Overweight Subjects With Cardiovascular Disease or Multiple Cardiovascular Risk Factors
A Randomized, Double-blind, Placebo-controlled, Parallel-group Study to Evaluate the Effect of Long-term Treatment With BELVIQ (Lorcaserin HCl) on the Incidence of Major Adverse Cardiovascular Events and Conversion to Type 2 Diabetes Mellitus in Obese and Overweight Subjects With Cardiovascular Disease or Multiple Cardiovascular Risk Factors
Status: Enrolling
Updated:  12/31/1969
UAB Medical Center
mi
from
Birmingham, AL
A Study to Evaluate the Effect of Long-term Treatment With BELVIQ (Lorcaserin HCl) on the Incidence of Major Adverse Cardiovascular Events and Conversion to Type 2 Diabetes Mellitus in Obese and Overweight Subjects With Cardiovascular Disease or Multiple Cardiovascular Risk Factors
A Randomized, Double-blind, Placebo-controlled, Parallel-group Study to Evaluate the Effect of Long-term Treatment With BELVIQ (Lorcaserin HCl) on the Incidence of Major Adverse Cardiovascular Events and Conversion to Type 2 Diabetes Mellitus in Obese and Overweight Subjects With Cardiovascular Disease or Multiple Cardiovascular Risk Factors
Status: Enrolling
Updated: 12/31/1969
UAB Medical Center
mi
from
Birmingham, AL
Click here to add this to my saved trials
A Study to Evaluate the Effect of Long-term Treatment With BELVIQ (Lorcaserin HCl) on the Incidence of Major Adverse Cardiovascular Events and Conversion to Type 2 Diabetes Mellitus in Obese and Overweight Subjects With Cardiovascular Disease or Multiple Cardiovascular Risk Factors
A Randomized, Double-blind, Placebo-controlled, Parallel-group Study to Evaluate the Effect of Long-term Treatment With BELVIQ (Lorcaserin HCl) on the Incidence of Major Adverse Cardiovascular Events and Conversion to Type 2 Diabetes Mellitus in Obese and Overweight Subjects With Cardiovascular Disease or Multiple Cardiovascular Risk Factors
Status: Enrolling
Updated:  12/31/1969
Mobile Heart Specialists, PC
mi
from
Mobile, AL
A Study to Evaluate the Effect of Long-term Treatment With BELVIQ (Lorcaserin HCl) on the Incidence of Major Adverse Cardiovascular Events and Conversion to Type 2 Diabetes Mellitus in Obese and Overweight Subjects With Cardiovascular Disease or Multiple Cardiovascular Risk Factors
A Randomized, Double-blind, Placebo-controlled, Parallel-group Study to Evaluate the Effect of Long-term Treatment With BELVIQ (Lorcaserin HCl) on the Incidence of Major Adverse Cardiovascular Events and Conversion to Type 2 Diabetes Mellitus in Obese and Overweight Subjects With Cardiovascular Disease or Multiple Cardiovascular Risk Factors
Status: Enrolling
Updated: 12/31/1969
Mobile Heart Specialists, PC
mi
from
Mobile, AL
Click here to add this to my saved trials